Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | HPGD | P15428 | 5/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19565507 | 0.82 | NISCH (0.44) | POLB | |
| SCHEMBL12610431 | 0.82 | NISCH (0.44) | POLB | |
| SCHEMBL406202 | 0.82 | NISCH (0.44) | POLB | |
| SCHEMBL406459 | 0.80 | POLB (0.43) | POLBCASP6ALDH1A1HPGDADRA1D | |
| SCHEMBL21346940 | 0.77 | POLB (0.50) | POLBCASP6ALDH1A1HPGDADRA1D | |
| SCHEMBL19393069 | 0.76 | CA2 (0.46) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL13652012 | 0.75 | CA2 (0.45) | L3MBTL1 | |
| SCHEMBL20618592 | 0.75 | MAPT (0.43) | ALDH1A1RAB9AKDM4EMAPTL3MBTL1 | |
| SCHEMBL17147894 | 0.75 | AKR1B1 (0.44) | — | |
| SCHEMBL13501482 | 0.75 | CYP19A1 (0.43) | ALDH1A1HPGDRAB9ATDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937096-B2 | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-8853263-B2 | Co-therapy for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| US-8716231-B2 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-06 | — | — | US | disclosed |
| US-8691867-B2 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-08 | — | — | US | disclosed |
| US-8497298-B2 | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-30 | — | — | US | disclosed |
| US-8492431-B2 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-07-23 | — | — | US | disclosed |
| US-20120065257-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | SMITH-SWINTOSKY VIRGINIA L (US) | 2012-03-15 | — | — | US | disclosed |
| US-8084490-B2 | Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-27 | — | — | US | disclosed |
| US-20090247618-A1 | PROCESS FOR PREPARATION OF BENZO-FUSED HETEROARYL DERIVATIVES | JANSSEN PHARMACEUTICA, N.C. (BE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247617-A1 | PROCESS FOR THE PREPARATION OF BENZO-FUSED HETEROARYL SULFAMATES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-01 | — | — | US | disclosed |
| US-20080027131-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-31 | — | — | US | disclosed |
| US-20070293440-A1 | O-fused heterocycle sulfonylurea compounds with another anticonvulsant or antiepileptic agent such as carbamazepine | JANSSEN PHARMACEUTICA NV (BE) | 2007-12-20 | — | — | US | disclosed |
| US-20070191474-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-16 | — | — | US | disclosed |
| US-20070155824-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155827-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155821-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR LOWERING LIPIDS AND LOWERING BLOOD GLUCOSE LEVELS | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155826-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155823-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155822-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155825-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155822-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | SULT2A1, OPRL1, NPSR1 | POLB 4523/4885CASP6 3727/4885ALDH1A1 181/4885 |
| US-20070155823-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS | SMN1; SMN2, BDNF, SIRT1 | POLB 4492/4885CASP6 281/4885ALDH1A1 379/4885 |
| US-20070155824-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS | STS, GABRB2, SULT2A1 | POLB 3558/4885CASP6 977/4885ALDH1A1 267/4885 |
| US-20070155827-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | SDHA, SQOR, SDHB | POLB 3070/4885CASP6 4243/4885ALDH1A1 254/4885 |
| US-20080027131-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY | GPR119, GLP1R, GIPR | POLB 4489/4885CASP6 3064/4885ALDH1A1 630/4885 |
| US-20070191474-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | CNR2, FAAH2, CCKBR | POLB 4390/4885CASP6 3872/4885ALDH1A1 1511/4885 |
| US-20070155825-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | SULT2A1, SULT1A1, STS | POLB 3379/4885CASP6 4482/4885ALDH1A1 26/4885 |
| US-20090247618-A1 | PROCESS FOR PREPARATION OF BENZO-FUSED HETEROARYL DERIVATIVES | CYP3A4, CYP3A5, CYP1A2 | POLB 1295/4885CASP6 2928/4885ALDH1A1 602/4885 |
| US-20090247617-A1 | PROCESS FOR THE PREPARATION OF BENZO-FUSED HETEROARYL SULFAMATES | STS, SULT2A1, GABRE | POLB 2324/4885CASP6 3580/4885ALDH1A1 874/4885 |
| US-20070293440-A1 | O-fused heterocycle sulfonylurea compounds with another anticonvulsant or antiepileptic agent such as carbamazepine | GABBR1, GABRB2, GABRE | POLB 4205/4885CASP6 2721/4885ALDH1A1 1032/4885 |
| US-20120065257-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | CNR2, FAAH2, CCKBR | POLB 4390/4885CASP6 3872/4885ALDH1A1 1511/4885 |
| US-20070155826-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER | GABBR1, GABBR2, SQOR | POLB 3579/4885CASP6 4111/4885ALDH1A1 503/4885 |
| US-20070155821-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR LOWERING LIPIDS AND LOWERING BLOOD GLUCOSE LEVELS | GPR119, LIPC, GLP1R | POLB 4324/4885CASP6 3334/4885ALDH1A1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.